10 August 2016
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of the transfer of its European and International commercial operations and related late-stage development programs to a newly-founded, private, pan-European ophthalmic specialty pharmaceutical company. This transfer includes the affiliates Nicox Pharma (France), together with its Spanish and UK operations, Nicox GmbH (Germany), Laboratoires Nicox (France) and Nicox Farma (Italy), all commercial products and the rights (and associated agreements) to AzaSite®, AzaSite Xtra®, BromSiteTM for Europe, Middle East and Africa and NCX 4240 outside of Japan and North America. No other Nicox affiliates, operations or programs are included in or affected by this transaction.
Nicox will receive a €9 million cash payment from GHO Capital as a result of the completion of this transaction. For further information on the transaction, please refer to Nicox’s Press Release dated July 5, 2016.